Business Overview: Kyverna Therapeutics, Inc. (NASDAQ: KYTX)

---

Executive Summary

Kyverna Therapeutics is a late-stage clinical biopharmaceutical company developing CAR T-cell therapies for autoimmune diseases — repurposing a technology proven in oncology (CAR T) for a very different patient population. Its lead candidate, miv-cel (KYV-101), an autologous anti-CD19 CAR T-cell therapy, has now been given to more than 100 autoimmune patients across multiple indications.

The company's most advanced program, in Stiff Person Syndrome (SPS), hit its registrational Phase 2 primary endpoint with high statistical significance (p=0.0003), and Kyverna plans to file a BLA in the first half of 2026 — a potential first-ever cell-therapy approval in autoimmune disease.

---

1. Core Business Model & How They Work

[ Patient Cell Collection ] ➡️ [ CAR T Manufacturing (autologous/allogeneic) ] ➡️ [ Lymphodepletion ] ➡️ [ One-Time CAR T Infusion ] ➡️ [ Durable Disease Remission (hypothesized) ]

Key Operational Drivers

1. One-and-done treatment paradigm: unlike chronic biologic therapies dosed indefinitely, CAR T aims for a single infusion with durable effect — a fundamentally different (and potentially premium-priced) value proposition versus standard-of-care biologics.
2. Multi-indication pipeline from one core asset: miv-cel is being tested in parallel across SPS, generalized myasthenia gravis (gMG), progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis — maximizing the value of a single manufacturing and regulatory investment.
3. Externalized manufacturing and licensing: Kyverna relies on manufacturing partners (ElevateBio BaseCamp, Minaris Advanced Therapies, Oxford Biomedica for lentiviral vectors) and licensed core IP (NIH for the CD19 CAR; Intellia for an allogeneic CRISPR-based follow-on), rather than owning the full manufacturing/IP stack itself.

---

2. Business Segments

Kyverna operates as a single clinical-stage R&D segment; no segment revenue split applies.

---

3. Product Portfolio / Pipeline

---

4. Competitive Landscape

• Existing biologic standard of care: Roche (Rituxan, Ocrevus — both CD20-targeted), AbbVie, Johnson & Johnson, Bristol Myers Squibb, and Novartis — large, established players whose chronic-dosing biologics are the current treatment paradigm Kyverna's one-time CAR T aims to disrupt.
• Direct cell/gene therapy competitors: Cabaletta Bio and Cartesian Therapeutics — both also pursuing CAR T or related cell-therapy approaches specifically for autoimmune disease, making this a genuine two-to-three-way race in a nascent category.

      AUTOIMMUNE CAR-T / CELL THERAPY LANDSCAPE
   High  ▲
Clinical  │      [KYVERNA - miv-cel]
Maturity  │  [Cartesian]
          │              [Cabaletta Bio]
   Low    └──────────────────────────────────►
         Narrow Indication            Broad Indication
                              Coverage

---

5. Strategic Strengths & Risks

Strengths

• Exclusive NIH license to the foundational CD19 CAR technology (two patent license agreements from May 2021), giving Kyverna a legally secured starting point for its core platform.
• Clinical lead in a first-mover indication: a statistically robust, registrational-quality SPS readout with a BLA filing already planned positions Kyverna as a potential first approved cell therapy in autoimmune disease.
• Pipeline optionality via KYV-102 (faster manufacturing) and KYV-201 (allogeneic, off-the-shelf) — both address CAR T's traditional weaknesses (long turnaround time, patient-specific manufacturing cost) if they succeed.
• Nine distinct patent families, with method-of-treatment protection on miv-cel running to 2042-2044, extending IP life well past the core CAR patent's 2035 nominal expiration.

Risks

• Direct competition from Cabaletta Bio and Cartesian Therapeutics in the same nascent autoimmune CAR T category, with no guarantee Kyverna's specific indications or data will prove superior.
• Manufacturing/scale dependency on external partners (ElevateBio, Minaris, Oxford Biomedica) introduces supply-chain and quality risk outside Kyverna's direct control.
• Milestone obligations: up to $64.5 million owed to Intellia under the allogeneic collaboration, plus NIH minimum annual royalties, add ongoing financial obligations even before commercial revenue exists.
• Binary regulatory risk on the SPS BLA filing and on each additional indication's data readout (gMG Phase 3, RA Phase 2 data expected 2026).

---

6. Financial Overview

---

7. Summary Conclusion

Kyverna Therapeutics is racing to become the first company to bring a CAR T-cell therapy to market for autoimmune disease, anchored by a statistically strong registrational SPS readout and a planned BLA filing in the first half of 2026. Its moat rests on an exclusive NIH-licensed core CAR technology, a deepening patent estate, and real clinical lead time against its two closest direct competitors, Cabaletta Bio and Cartesian Therapeutics — but the company remains dependent on external manufacturing partners and faces binary regulatory risk across multiple parallel indications, meaning its long-term competitive position will be decided largely by whether its BLA and subsequent indication filings succeed on the clinical and regulatory timelines it has laid out.